BACKGROUND: Small studies have reported women to have worse outcomes and more adverse events after implantation of mechanical circulatory support device compared with men. To further evaluate sex differences in outcome, we used the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). METHODS AND RESULTS: There were 401 women (pulsatile devices=78) and 1535 men (pulsatile devices=402) from 89 institutions who were prospectively enrolled into the INTERMACS database for primary implantation of a left ventricular assist device (LVAD) between June 23, 2006, and March 31, 2010. Extensive preimplantation and outcome data were collected on all patients. With a mean follow-up of 7 months, 67 females (17%) died and 250 males (16%) died. There was no statistically significant sex difference in mortality for either pulsatile-flow (P=0.82) or continuous-flow (P=0.95) devices in adjusted and unadjusted models. There were also no statistically significant sex differences with time to first infection, bleeding, or device malfunction. However, female sex was associated with an increased hazard of first neurological event (adjusted hazard ratio, 1.44; 95% CI, 1.05-1.96; P=0.020). CONCLUSIONS: There were no significant sex differences in mortality, time to first infection, bleeding, or device malfunction with either pulsatile- or continuous-flow LVADs. However, women had an increased risk of first neurological event. For urgent/emergent mechanical support, the benefit of LVAD support likely outweighs the risk, but it remains less clear for women undergoing elective LVAD implantation.
RCT Entities:
BACKGROUND: Small studies have reported women to have worse outcomes and more adverse events after implantation of mechanical circulatory support device compared with men. To further evaluate sex differences in outcome, we used the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). METHODS AND RESULTS: There were 401 women (pulsatile devices=78) and 1535 men (pulsatile devices=402) from 89 institutions who were prospectively enrolled into the INTERMACS database for primary implantation of a left ventricular assist device (LVAD) between June 23, 2006, and March 31, 2010. Extensive preimplantation and outcome data were collected on all patients. With a mean follow-up of 7 months, 67 females (17%) died and 250 males (16%) died. There was no statistically significant sex difference in mortality for either pulsatile-flow (P=0.82) or continuous-flow (P=0.95) devices in adjusted and unadjusted models. There were also no statistically significant sex differences with time to first infection, bleeding, or device malfunction. However, female sex was associated with an increased hazard of first neurological event (adjusted hazard ratio, 1.44; 95% CI, 1.05-1.96; P=0.020). CONCLUSIONS: There were no significant sex differences in mortality, time to first infection, bleeding, or device malfunction with either pulsatile- or continuous-flow LVADs. However, women had an increased risk of first neurological event. For urgent/emergent mechanical support, the benefit of LVAD support likely outweighs the risk, but it remains less clear for women undergoing elective LVAD implantation.
Authors: Adrian F Hernandez; Joshua D Grab; James S Gammie; Sean M O'Brien; Bradley G Hammill; Joseph G Rogers; Margarita T Camacho; Mercedes K Dullum; T Bruce Ferguson; Eric D Peterson Journal: Circulation Date: 2007-07-23 Impact factor: 29.690
Authors: Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier Journal: N Engl J Med Date: 2007-08-30 Impact factor: 91.245
Authors: Francis D Pagani; Leslie W Miller; Stuart D Russell; Keith D Aaronson; Ranjit John; Andrew J Boyle; John V Conte; Roberta C Bogaev; Thomas E MacGillivray; Yoshifumi Naka; Donna Mancini; H Todd Massey; Leway Chen; Charles T Klodell; Juan M Aranda; Nader Moazami; Gregory A Ewald; David J Farrar; O Howard Frazier Journal: J Am Coll Cardiol Date: 2009-07-21 Impact factor: 24.094
Authors: Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Jennifer C Matthews; Francis D Pagani; Jonathan W Haft; Todd M Koelling; David C Naftel; Keith D Aaronson Journal: Circulation Date: 2010-01-04 Impact factor: 29.690
Authors: Sarah T Ward; Qixing Liang; Francis D Pagani; Min Zhang; Robert L Kormos; Keith D Aaronson; Andrew D Althouse; Brahmajee K Nallamothu; Donald S Likosky Journal: J Heart Lung Transplant Date: 2017-06-23 Impact factor: 10.247
Authors: Eileen M Hsich; Eugene H Blackstone; Lucy Thuita; Dennis M McNamara; Joseph G Rogers; Hemant Ishwaran; Jesse D Schold Journal: Circ Heart Fail Date: 2017-06 Impact factor: 8.790
Authors: Gennaro Giustino; Jessica Overbey; Doris Taylor; Gorav Ailawadi; Katherine Kirkwood; Joseph DeRose; Marc A Gillinov; François Dagenais; Mary-Lou Mayer; Alan Moskowitz; Emilia Bagiella; Marissa Miller; Paul Grayburn; Peter K Smith; Annetine Gelijns; Patrick O'Gara; Michael Acker; Anuradha Lala; Judy Hung Journal: JACC Heart Fail Date: 2019-06 Impact factor: 12.035
Authors: Garrick C Stewart; Thomas Cascino; Blair Richards; Shokoufeh Khalatbari; Douglas L Mann; Wendy C Taddei-Peters; J Timothy Baldwin; Neal O Jeffries; Catherine Spino; Lynne W Stevenson; Keith D Aaronson Journal: JACC Heart Fail Date: 2019-05-08 Impact factor: 12.035